Literature DB >> 19162393

Functional phenotyping and genotyping of circulating tumor cells from patients with castration resistant prostate cancer.

Pamela L Paris1, Yasuko Kobayashi, Qiang Zhao, Wei Zeng, Shivaranjani Sridharan, Tina Fan, Howard L Adler, Emmanuel R Yera, M H Zarrabi, Stanley Zucker, Jeffry Simko, Wen-Tien Chen, Jonathan Rosenberg.   

Abstract

Circulating tumor cells (CTCs) hold promise for studying advanced prostate cancer. A functional collagen adhesion matrix (CAM) assay was used to enrich CTCs from prostate cancer patients' blood. CAM ingestion and epithelial immuno-staining identified CTCs, which were genotyped using oligonucleotide array comparative genomic hybridization. The highest CTC counts were observed in men with metastatic castration resistant prostate cancer (CRPC) compared to castration sensitive prostate cancer. Copy number profiles for CRPC CTCs were similar to paired solid tumor DNA, and distinct from corresponding DNA from the residual CAM-depleted blood. CAM CTC enrichment may allow cellular and genetic analyses in prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19162393     DOI: 10.1016/j.canlet.2008.12.007

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  39 in total

Review 1.  Isolated, disseminated and circulating tumour cells in prostate cancer.

Authors:  David Schilling; Tilman Todenhöfer; Jörg Hennenlotter; Christian Schwentner; Tanja Fehm; Arnulf Stenzl
Journal:  Nat Rev Urol       Date:  2012-07-10       Impact factor: 14.432

Review 2.  Materials and microfluidics: enabling the efficient isolation and analysis of circulating tumour cells.

Authors:  Joshua M Jackson; Małgorzata A Witek; Joyce W Kamande; Steven A Soper
Journal:  Chem Soc Rev       Date:  2017-07-17       Impact factor: 54.564

3.  Using circulating tumor cells to advance precision medicine in prostate cancer.

Authors:  Giuseppe Galletti; Daniel Worroll; David M Nanus; Paraskevi Giannakakou
Journal:  J Cancer Metastasis Treat       Date:  2017-09-27

4.  Entrapment of Prostate Cancer Circulating Tumor Cells with a Sequential Size-Based Microfluidic Chip.

Authors:  Xiang Ren; Brittni M Foster; Parham Ghassemi; Jeannine S Strobl; Bethany A Kerr; Masoud Agah
Journal:  Anal Chem       Date:  2018-06-01       Impact factor: 6.986

5.  Isolation of circulating epithelial and tumor progenitor cells with an invasive phenotype from breast cancer patients.

Authors:  Janice Lu; Tina Fan; Qiang Zhao; Wei Zeng; Eva Zaslavsky; John J Chen; Michael A Frohman; Marc G Golightly; Stefan Madajewicz; Wen-Tien Chen
Journal:  Int J Cancer       Date:  2010-02-01       Impact factor: 7.396

6.  Clinical utility of circulating tumor cells in non-small-cell lung carcinoma: are we there yet?

Authors:  Milica Kontic; Miodrag Ognjanovic; Dragana Jovanovic; Simona Ognjanovic
Journal:  J Thorac Dis       Date:  2012-10       Impact factor: 2.895

7.  Technical Insights into Highly Sensitive Isolation and Molecular Characterization of Fixed and Live Circulating Tumor Cells for Early Detection of Tumor Invasion.

Authors:  Sophie Laget; Lucile Broncy; Katia Hormigos; Dalia M Dhingra; Fatima BenMohamed; Thierry Capiod; Magne Osteras; Laurent Farinelli; Stephen Jackson; Patrizia Paterlini-Bréchot
Journal:  PLoS One       Date:  2017-01-06       Impact factor: 3.240

Review 8.  Circulating tumour cells-monitoring treatment response in prostate cancer.

Authors:  David T Miyamoto; Lecia V Sequist; Richard J Lee
Journal:  Nat Rev Clin Oncol       Date:  2014-05-13       Impact factor: 66.675

9.  Treatment monitoring of patients with epithelial ovarian cancer using invasive circulating tumor cells (iCTCs).

Authors:  Michael L Pearl; Huan Dong; Shaun Tulley; Qiang Zhao; Marc Golightly; Stanley Zucker; Wen-Tien Chen
Journal:  Gynecol Oncol       Date:  2015-03-11       Impact factor: 5.482

Review 10.  Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA.

Authors:  Daniel A Haber; Victor E Velculescu
Journal:  Cancer Discov       Date:  2014-05-06       Impact factor: 39.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.